Jason Butler
Stock Analyst at Citizens
(4.68)
# 180
Out of 5,111 analysts
144
Total ratings
51.7%
Success rate
48.49%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $9.97 | +90.57% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $63.45 | +45.00% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $5.91 | +103.05% | 8 | Oct 9, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $117.91 | -19.43% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $29.60 | -5.41% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $27.26 | +35.73% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $12.49 | +212.37% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $3.81 | +57.48% | 11 | Jun 12, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $36.19 | +176.32% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $33.03 | +15.05% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $78 | $62.16 | +25.48% | 16 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.17 | +120.32% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.78 | +5.82% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $850.95 | -17.62% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.85 | +204.15% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $1.63 | +452.15% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.85 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.33 | +67.70% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $3.59 | +512.81% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.04 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $10.27 | +408,858.13% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $14.87 | +680.09% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.95 | +81.82% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.56 | - | 1 | Dec 2, 2020 |
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $9.97
Upside: +90.57%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $63.45
Upside: +45.00%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $5.91
Upside: +103.05%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $117.91
Upside: -19.43%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $29.60
Upside: -5.41%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $27.26
Upside: +35.73%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $12.49
Upside: +212.37%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.81
Upside: +57.48%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $36.19
Upside: +176.32%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $33.03
Upside: +15.05%
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $62.16
Upside: +25.48%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.17
Upside: +120.32%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.78
Upside: +5.82%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $850.95
Upside: -17.62%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.85
Upside: +204.15%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $1.63
Upside: +452.15%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.85
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $11.33
Upside: +67.70%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $3.59
Upside: +512.81%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.04
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $10.27
Upside: +408,858.13%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $14.87
Upside: +680.09%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.95
Upside: +81.82%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.56
Upside: -